Iridex Corp IRIX
We take great care to ensure that the data presented and summarized in this overview for IRIDEX CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRIX
View all-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX1MShares$1.73 Million3.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$970,6960.0% of portfolio
-
Amh Equity LTD501KShares$866,9391.21% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny397KShares$687,4320.0% of portfolio
-
Geode Capital Management, LLC Boston, MA131KShares$226,9270.0% of portfolio
-
Ars Investment Partners, LLC114KShares$196,4670.02% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR100KShares$173,0000.01% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX77KShares$133,1660.0% of portfolio
-
Apexium Financial, LP65.7KShares$113,6520.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA65.4KShares$113,1290.0% of portfolio
Latest Institutional Activity in IRIX
Top Purchases
Top Sells
About IRIX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Insider Transactions at IRIX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 07
2024
|
Patrick Mercer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+33.71%
|
-
|
Jul 04
2024
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,073
-1.06%
|
$4,146
$2.07 P/Share
|
Jul 04
2024
|
David Bruce CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,788
-3.65%
|
$9,576
$2.07 P/Share
|
Jun 30
2024
|
David Bruce CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,098
-5.13%
|
$14,196
$2.16 P/Share
|
Jun 30
2024
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,123
-2.07%
|
$8,246
$2.16 P/Share
|
May 22
2024
|
Patrick Mercer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+37.57%
|
-
|
Jul 04
2023
|
David Bruce CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,640
-3.24%
|
$9,280
$2.14 P/Share
|
Jul 04
2023
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,015
-2.47%
|
$4,030
$2.14 P/Share
|
Jun 30
2023
|
David Bruce CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,112
-6.6%
|
$20,224
$2.17 P/Share
|
Jun 30
2023
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,828
-6.68%
|
$11,656
$2.17 P/Share
|
Jun 14
2023
|
Ken Ludlum Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,267
+27.85%
|
$39,267
$1.91 P/Share
|
Jun 14
2023
|
Scott Shuda Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,267
+26.65%
|
$39,267
$1.91 P/Share
|
Jun 14
2023
|
Beverly A Huss Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,267
+37.04%
|
$39,267
$1.91 P/Share
|
Jun 14
2023
|
Robert Earle Grove Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,267
+19.7%
|
$39,267
$1.91 P/Share
|
Jun 14
2023
|
Nandini Devi Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,267
+33.73%
|
$39,267
$1.91 P/Share
|
Oct 30
2022
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-0.08%
|
$142
$2.27 P/Share
|
Oct 27
2022
|
Patrick Mercer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
35,570
+28.94%
|
-
|
Oct 27
2022
|
David Bruce CEO |
BUY
Grant, award, or other acquisition
|
Direct |
59,730
+28.06%
|
-
|
Sep 30
2022
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
72
-0.14%
|
$144
$2.41 P/Share
|
Aug 30
2022
|
Patrick Mercer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
71
-0.14%
|
$142
$2.55 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 320K shares |
---|
Payment of exercise price or tax liability | 18.1K shares |
---|